March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bio's lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The company's pipeline is designed to expand on these early successes to more broadly impact other high-challenge cancers.

March Biosciences

Sarah Hein

Steven Lehmann

Alice Bexon

Peter Olagunju

Federica Giordano

Doris Sanchez

Max Mamonkin

Clinical Development and Strategy

Leadership Team

Teams at March Biosciences

Clinical Development and Strategy

Leadership Team